a drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. oprelvekin is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. it is a type of biological response modifier. also called neumega, recombinant human interleukin-11, and rhil-11.
| human | 遺伝子名 | Oprelvekin |
| 同義語(エイリアス) | AGIF; IL11; Adipogenesis inhibitory factor; interleukin 11; Interleukin-11 precursor; IL-11 | |
| SWISS-PROTのID | SWISS-PROT:P20809 | |
| EntrezGeneのID | EntrezGene:3589 | |
| その他のDBのID | HGNC:5966 |
本文中に表示されているデータベースの説明
出典:Wiktionary
出典:『Wiktionary』 (2012/10/20 13:46 UTC 版)
oprelvekin (uncountable)
出典:Wikipedia
出典:『Wikipedia』 (2011/07/23 10:30 UTC 版)
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.